Sahajanand Medical Technologies IPO
Live MainboardAlready have an account? Apply now
Sahajanand Medical Technologies IPO details
Schedule of Sahajanand Medical Technologies
| Issue open date | 15 Oct 2026 |
| Issue close date | 19 Oct 2026 |
| UPI mandate deadline | 19 Oct 2026 (5 PM) |
| Allotment finalization | 21 Oct 2026 |
| Refund initiation | 22 Oct 2026 |
| Share credit | 22 Oct 2026 |
| Listing date | 23 Oct 2026 |
| Mandate end date | 03 Nov 2026 |
| Lock-in end date for anchor investors (50%) | 19 Nov 2026 |
| Lock-in end date for anchor investors (remaining) | 18 Jan 2027 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Sahajanand Medical Technologies
Sahajanand Medical Technologies develops, manufactures, and markets cardiovascular devices globally. The core business is divided into two primary segments: vascular intervention products, such as coronary stents and balloon catheters, and structural heart devices, including transcatheter aortic valves and occluders. The company generates the majority of its revenue from the sale of vascular intervention devices, with the Supraflex Cruz, a biodegradable polymer-based drug-eluting stent, acting as a major contributor to its sales. Products are distributed across India, Europe, and the rest of the world through a combination of direct, hybrid, and distributor-led models, supported by an extensive network of domestic and international distributors. Operations are backed by manufacturing facilities located in Surat, Hyderabad, and Thailand. Additionally, the business relies heavily on dedicated research and development capabilities to continually enhance existing products and introduce new cardiovascular treatments.
Financials of Sahajanand Medical Technologies
Issue size
| Funds Raised in the IPO | Amount (₹ crores) |
| Total issue size | 475.48 |
| Offer for sale – Proceeds go to the existing investors | 475.48 |
Strengths
- Strong portfolio of vascular and structural heart medical devices
- Extensive domestic and international distribution network
- Dedicated in-house research and development capabilities
- Multiple manufacturing facilities across India and Thailand
- Diversified revenue streams from sales in over 65 countries
Risks
- High dependency on revenues from the Supraflex Cruz stent
- Stringent domestic and global regulatory compliance requirements
- Vulnerability to foreign currency exchange rate fluctuations
- Reliance on limited third-party suppliers for key raw materials
- Exposure to pricing controls and healthcare reimbursement caps